This TMEM160-TRIM37-KEAP1/NRF2 axis not only highlights a critical regulatory pathway in GC but also suggests potential therapeutic targets to enhance the efficacy of treatments by overcoming ferroptosis resistance. This evidence concerns the gene NFE2L2 and gastric cancer.